Medication info
Sitagliptin Prolonged-Release Tablets 50/500 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Sitagliptin Prolonged-Release Tablets 50/500 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hallym Pharmaceutical Co., Ltd.
Appearance
Bright blue, oval-shaped, biconvex prolonged-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202080 · Approved 2022.05.17 · Insurance code 645306880

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with meals once daily, preferably in the evening, and increase the dose gradually. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg plus their current dose of metformin. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine, 50/1000 mg extended-release, once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Hallym Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by administering sitagliptin and metformin together. When used alongside dietary and exercise therapy, it effectively improves blood sugar levels. This contributes to better diabetes management and helps maintain health.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with meals once daily, preferably in the evening, and increase the dose gradually. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg plus their current dose of metformin. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine, 50/1000 mg extended-release, once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains both sitagliptin and metformin. Due to potential precautions, it is crucial to follow the doctor's or pharmacist's instructions carefully. First, this medication can cause allergic reactions; therefore, if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur after administration, immediately discontinue use and visit a hospital. Additionally, there is a risk of pancreatitis, a serious pancreatic condition; if symptoms such as abdominal pain, nausea, vomiting, or fever arise, notify healthcare professionals immediately. Patients with impaired kidney function, dehydration, severe infections, or heart diseases should avoid taking this medication. Especially in cases of moderate to severe renal impairment, administration is contraindicated. This medication should be temporarily discontinued before and after tests using iodine contrast agents, and can be resumed after confirming normal kidney function. Women who are pregnant or may become pregnant, and nursing mothers should not take this medication. This medication can cause hypoglycemia; therefore, caution is needed if irregular eating, insufficient food intake, or excessive exercise occurs. The risk of hypoglycemia may increase when taken with other blood sugar-lowering agents, so consult a doctor. Gastrointestinal side effects (diarrhea, nausea, vomiting, abdominal pain) may occur during treatment, and if these symptoms are severe, inform a healthcare professional. Patients with poor liver function or severe lung disease are also advised to avoid this medication. There is a rare but serious risk of lactic acidosis associated with this medication, so if symptoms such as weakness, muscle pain, difficulty breathing, or abdominal pain occur, immediately discontinue use and seek hospital care. Additionally, regular monitoring of kidney function and blood tests is advisable, and it is recommended to check vitamin B12 levels as well. Excessive alcohol intake increases the risk of side effects, so it is safer to avoid drinking while on this medication. Treatment should be interrupted for a certain period before and after surgery, and can be resumed after confirming normal kidney function and oral intake post-surgery. This medication has not been established for safety and efficacy in children or adolescents under 18, so it is advised not to use it in these groups. Older adults may have reduced kidney function, so dosage adjustments should be made under a doctor's supervision, and regular kidney function tests should be conducted. In case of overdose, contact a medical institution immediately for appropriate treatment, as some of this medication can be removed through hemodialysis. During the use of this medication, it is important to consult with the doctor and immediately report any symptoms or adverse reactions that occur.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 18 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute kidney failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from exposure to air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright blue, oval-shaped, biconvex prolonged-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.